Huapont Life Sciences Co.,Ltd

Equities

002004

CNE000001JJ6

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-30 pm EDT 5-day change 1st Jan Change
4.63 CNY -0.22% Intraday chart for Huapont Life Sciences Co.,Ltd +1.09% -0.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024 CI
Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023 CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Huapont Life Sciences Co.,Ltd's Equity Buyback Plan announced on December 28, 2023. CI
Huapont Life Sciences Co.,Ltd announces an Equity Buyback for CNY 30 million worth of its shares. CI
Huapont Life Sciences Co.,Ltd authorizes a Buyback Plan. CI
Huapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component A Share Index CI
Huapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component Index CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023 CI
Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022 CI
Huapont Life Sciences Co.,Ltd Proposes Final Cash Dividend for the Year 2022 CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Huapont Life Sciences Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Huapont Life Sciences Forms 100 Million Yuan Drug Research, Information Sharing Center MT
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Huapont Life Sciences Co., Ltd. Announces Dividend on A Shares for the Year 2021, Payable on June 2, 2022 CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Huapont Life Sciences Co., Ltd. Approves Profit Distribution for 2021 CI
Huapont Life Sciences Maintains Final 2021 Dividend as Full-Year Profit Rises 2.8% MT
Huapont Life Sciences Co., Ltd. Proposes Final Cash Dividend for 2021 CI
Huapont Life Sciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chart Huapont Life Sciences Co.,Ltd
More charts
HUAPONT LIFE SCIENCES CO., LTD. is a China-based company principally engaged in the research and development, manufacture and sales of pesticide chemical products. The Company operates through three segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sales of skin pharmaceuticals, antituberculous pharmaceuticals and other manufactured products. Its products include fleroxacin and ambroxol hydrochloride for injection, and lecithin-bound iodine capsules, among others. The Pesticide Chemical segment is engaged in the production and sales of pesticides and other fine chemicals, including herbicides, bactericides and insecticides, among others. The Bulk Drug segment is engaged in the research and development and manufacture of bulk drugs and medical intermediates. The Company is also engaged in the provision of travel services, the sales of tea and the provision of technical services, among others.
More about the company
  1. Stock Market
  2. Equities
  3. 002004 Stock
  4. News Huapont Life Sciences Co.,Ltd
  5. Huapont Life Sciences Maintains Final 2021 Dividend as Full-Year Profit Rises 2.8%